Loading...
Date of Award
Spring 2024
Degree Name
Master of Medical Science (Physician Assistant)
Department
Physician Assistant; College of Health Sciences
First Advisor
Michelle Thal
Abstract
Atopic Dermatitis (AD) is one of the most common skin conditions, affecting approximately 10% of all individuals in the United States. Existing therapies for AD include emollients, moisturizers, topical corticosteroids, phototherapy, and more. However, over 55% of all individuals affected by moderate-to-severe AD report insufficient symptom control despite treatment with initial therapies. There have been several recent advancements in injectable and biologic therapies for atopic dermatitis, with many biologic drugs receiving U.S. Food and Drug Administration (FDA) approval for AD in the past 3 years. Due to the recent advancements in biologic therapies for AD, there are scant reviews explaining safety, efficacy, and indications for use regarding these medications. This review discusses the year of FDA approval, mechanism of action (MOA), indications, route, dosage, frequency, contraindications, drug to drug interactions (DDIs), adverse effects, safety, and efficacy of Dupixent (dupilumab), Adbry (tralokinumab-ldrm), Rinvoq (upadacitinib), Opzelura (ruxolitinib), and Eucrisa (crisaborole). This paper will act as a reference where providers can review and compare potential biologic therapies for AD patients.
Recommended Citation
Bogert, Camryn, "A Review of Biologic Therapies for Refractory Atopic Dermatitis" (2024). Capstone Showcase. 18.
https://scholarworks.arcadia.edu/showcase/2024/pa/18
Additional Files
A Review of Biologic Therapies for Refractory Atopic Dermatitis- final pdf.pdf (713 kB)Atopic Dermatitis_PA Capstone Poster.pdf (15316 kB)
A Review of Biologic Therapies for Refractory Atopic Dermatitis
Atopic Dermatitis (AD) is one of the most common skin conditions, affecting approximately 10% of all individuals in the United States. Existing therapies for AD include emollients, moisturizers, topical corticosteroids, phototherapy, and more. However, over 55% of all individuals affected by moderate-to-severe AD report insufficient symptom control despite treatment with initial therapies. There have been several recent advancements in injectable and biologic therapies for atopic dermatitis, with many biologic drugs receiving U.S. Food and Drug Administration (FDA) approval for AD in the past 3 years. Due to the recent advancements in biologic therapies for AD, there are scant reviews explaining safety, efficacy, and indications for use regarding these medications. This review discusses the year of FDA approval, mechanism of action (MOA), indications, route, dosage, frequency, contraindications, drug to drug interactions (DDIs), adverse effects, safety, and efficacy of Dupixent (dupilumab), Adbry (tralokinumab-ldrm), Rinvoq (upadacitinib), Opzelura (ruxolitinib), and Eucrisa (crisaborole). This paper will act as a reference where providers can review and compare potential biologic therapies for AD patients.